This study is for women in menopause with hot flashes
A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
Study Length: This study will consist of a screening period and a 52-week treatment period. Safety follow up will occur 3 weeks after the last dose of study drug
Target Age/Sex: 40 Years to 65 Years , Female
Participants will receive at no cost: Study medication and study related procedures. Subject may also receive a stipend for time/travel related to the study.